Date: 2014-09-17
Type of information: IPO
Company: Affimed (Germany)
Investors:
Amount: $ 56 million
Funding type: IPO
Planned used:
Others: * On September 17, 2014, Affimed Therapeutics announced the closing of its initial public offering of 8,000,000 common shares at an initial public offering price of $7.00 per common share. In addition, Affimed has granted the underwriters a 30- day option to purchase up to an additional 1,200,000 common shares from Affimed at the public offering price, less underwriting discounts. * On September 12, 2014, Affimed Therapeutics announced the pricing of its initial public offering of 8,000,000 common shares at an initial public offering price of $7.00 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 common shares from Affimed at the public offering price, less underwriting discounts. The offering is expected to close on or about September 17, 2014, subject to customary closing conditions. Affimed\'s common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the symbol \"AFMD\" on September 12, 2014. * On June 30, 2014, Affimed Therapeutics announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common shares. The number of shares to be
offered and the price range for the offering have not yet been determined. Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Trout Capital LLC is acting as co-manager.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
Therapeutic area: Cancer - Oncology
